Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Frontiers in Oncology|August 9, 2021
Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy BiomarkersSameh Daher, Yaacov R Lawrence, Elizabeth Dudnik, et al.
Molecular and Clinical Oncology|April 11, 2019
Locally advanced rectal adenocarcinoma: Are preoperative short and long course radiotherapy truly equivalent?Ofer Margalit, Ronac Mamtani, Yaacov R Lawrence, et al.
Journal of Cancer Research and Clinical Oncology|January 23, 2022
Benefit for single-agent adjuvant chemotherapy in elderly patients with locally advanced gastric adenocarcinomaOfer Margalit, Shun Yu, Einat Shacham-Shmueli, et al.
The Oncologist|January 31, 2019
Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal AdenocarcinomaOfer Margalit, Ronac Mamtani, Scott Kopetz, et al.
European Heart Journal Open|November 13, 2025
Increased cardiovascular risk among cancer survivors presenting with chest painKobi Faierstein, Rotem Tal-Ben Ishay, Ranel Loutati, et al.
The Israel Medical Association Journal : IMAJ|May 1, 2017
Stereotactic Ablative Body Radiation for Stage I Lung Cancer in Israel: A Retrospective Single-Center ReportSarit Appel, Yaacov R Lawrence, Jeffery Goldstein, et al.
International Journal of Radiation Oncology, Biology, Physics|March 8, 2022
Single-Fraction Celiac Plexus Radiosurgery: A Preliminary Proof-of-Concept Phase 2 Clinical TrialLiat Hammer, David Hausner, Maoz Ben-Ayun, et al.
Cancer Investigation|September 4, 2023
Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal AdenocarcinomaOfer Margalit, Einat Shacham-Shmueli, Gal Strauss, et al.
Pharmacoepidemiology and Drug Safety|March 21, 2020
Assessing the effects of beta-blockers on pancreatic cancer risk: A nested case-control studyAkram Saad, Jeffrey Goldstein, Ofer Margalit, et al.
Journal for Immunotherapy of Cancer|August 4, 2025
Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung studyFrancois Ghiringhelli, Yaacov R Lawrence, Enriqueta Felip, et al.
Pageof 6